Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
23.78
-0.18 (-0.75%)
At close: Aug 17, 2026, 4:00 PM EDT
23.88
+0.10 (0.42%)
After-hours: Aug 17, 2026, 4:21 PM EDT
Surrozen Revenue
Surrozen had revenue of $5.00M in the quarter ending June 30, 2026, with 408.65% growth. This brings the company's revenue in the last twelve months to $11.51M, down -8.79% year-over-year. In the year 2025, Surrozen had annual revenue of $3.48M, down -67.37%.
Revenue (ttm)
$11.51M
Revenue Growth
-8.79%
P/S Ratio
24.28
Revenue / Employee
$261,614
Employees
44
Market Cap
279.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.48M | -7.18M | -67.37% |
| Dec 31, 2024 | 10.66M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 61.21M |
| ProQR Therapeutics | 21.05M |
| Sol-Gel Technologies | 18.47M |
| Lineage Cell Therapeutics | 13.08M |
| Entrada Therapeutics | 4.69M |
SRZN News
- 11 days ago - Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Surrozen Quarterly report: Q2 2026 - Filings
- 11 days ago - Surrozen Earnings release: Q2 2026 - Filings
- 26 days ago - Surrozen Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - Transcripts
- 4 weeks ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 3 months ago - Surrozen Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 3 months ago - Surrozen Transcript: AGM 2026 - Transcripts
- 3 months ago - Surrozen price target raised to $44 from $36 at H.C. Wainwright - TheFly